PROTACs are effective in addressing the platelet toxicity associated with BCL-X_L inhibitors.

ABSTRACT: BCL-X_L is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-X_L has also been identified as a key survival factor in senescent cells. Accumulation of senescent cells has been indicated as a causal factor of aging and many age-related diseases and contributes to tumor relapse and metastasis. Thus, inhibition of BCL-X_L is an attractive strategy for the treatment of cancer and extension of healthspan. However, development of BCL-X_L inhibitors such as navitoclax for clinical use has been challenging because human platelets depend on BCL-X_L for survival. In this review, we discuss how BCL-X_L-targeted proteolysis targeting

SUBMITTER: Zhang P 

PROVIDER: S-EPMC8293695 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature